| Abstrakt: |
A study published in the journal CANCER reveals that the out-of-pocket costs for additional diagnostic testing following abnormal prostate cancer screening results are substantial, common, and rising for privately insured men. The study analyzed data from over 3 million US men aged 55-69 who underwent PSA screening between 2010 and 2020. The findings highlight the financial burden that these costs place on patients and suggest that insurance companies should provide full coverage for necessary diagnostic tests to ensure that patients can access recommended screening. The researchers recommend that policymakers and insurance companies eliminate cost-sharing for patients and offer full coverage for testing throughout the screening pathway. [Extracted from the article] |
